Skip to main content
Clinical Trials/NCT06870760
NCT06870760RecruitingNot Applicable

Pre-malignant States to Hematologic Malignancies in Firefighters

Wake Forest University Health Sciences2 sites in 1 country300 target enrollmentStarted: June 23, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
300
Locations
2
Primary Endpoint
Clonal Hematopoiesis (CHIP)

Study Overview

Brief Summary

The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

Detailed Description

Firefighters from the Charlotte Fire Department, ages 40-49 and with at least 5 years on the job experience will be offered consent for this study. Consented and eligible participants will have labs collected at the Baseline visit to evaluate for CHIP and monoclonal gammopathy. Buccal swabs (also collected at Baseline) and any remaining blood from the Baseline labs will be collected from participants who consent to collection and banking of their samples for future research. Participants will also complete the Firefighter History Assessment at Baseline.

If clonal hematopoiesis (CHIP) results are interpreted by the investigator as abnormal, the participant will be given a clinical referral if indicated for discussion of diagnosis, potential further diagnostic tests, and implications per standard CHIP management guidelines. If monoclonal gammopathy or other (concerning) abnormality of the complete blood count is detected, the participant will be provided a referral for a clinic visit for diagnostic assessments and followed up per standard of care.

If the participant proceeds with the referral and diagnostic work-up, the final diagnosis (if any) resulting from the initial diagnostic assessment(s) will be collected

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
40 Years to 49 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Written informed consent and HIPAA authorization for release of personal health information.
  • Age ≥ 40-49 years at the time of consent (self-reported)
  • Ability of the participant to understand and comply with study procedures for the entire length of the study
  • Currently employed by Charlotte Fire Department (CFD) with at least 5 years on-the -job experience (self-reported)

Exclusion Criteria

  • Anyone with a current diagnosis of a hematologic malignancy will be excluded.

Arms & Interventions

Firefighter

Participants employed by the Charlotte Fire Department (CFD) with at least 5 years of on-the-job experience between the ages of 40 and 49

Intervention: Monoclonal Gammopathy (Other)

Firefighter

Participants employed by the Charlotte Fire Department (CFD) with at least 5 years of on-the-job experience between the ages of 40 and 49

Intervention: Complete Blood Count with differential (CBC w/ diff) (Other)

Firefighter

Participants employed by the Charlotte Fire Department (CFD) with at least 5 years of on-the-job experience between the ages of 40 and 49

Intervention: Clonal hematopoiesis (CHIP) (Other)

Outcomes

Primary Outcomes

Clonal Hematopoiesis (CHIP)

Time Frame: From enrollment to availability of lab results, approximately 6 months

The presence of positive somatic mutation will be determined for each enrolled participant as a binary variable indicating if the participant is harboring clonal hematopoiesis.

Secondary Outcomes

  • Monoclonal Gammopathy (MGUS)(From enrollment to availability of lab results, approximately 1 week)
  • Targeted Diagnoses Rate(up to 12 months after all labs have resulted)
  • Baseline Survey Results(Baseline)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Pre-malignant States to Hematologic... | Clinical Trial